GreenLight Biosciences Holdings, (GRNA): Price and Financial Metrics


GreenLight Biosciences Holdings, (GRNA): $1.09

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GRNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GRNA POWR Grades

  • GRNA scores best on the Sentiment dimension, with a Sentiment rank ahead of 93.03% of US stocks.
  • The strongest trend for GRNA is in Sentiment, which has been heading up over the past 179 days.
  • GRNA's current lowest rank is in the Momentum metric (where it is better than 15.29% of US stocks).

GRNA Stock Summary

  • GRNA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 3.37% of US stocks.
  • In terms of volatility of its share price, GRNA is more volatile than 97.38% of stocks we're observing.
  • GREENLIGHT BIOSCIENCES HOLDINGS PBC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -138.86%, greater than the shareholder yield of just 4.01% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to GREENLIGHT BIOSCIENCES HOLDINGS PBC, a group of peers worth examining would be ARDS, NVAX, TMDI, TCRX, and IVA.
  • To dig deeper into the stock's financial statements, go to GRNA's page on browse-edgar?action=getcompany&CIK=0001822691.

GRNA Valuation Summary

  • In comparison to the median Healthcare stock, GRNA's price/earnings ratio is 104.98% lower, now standing at -1.1.
  • Over the past 25 months, GRNA's price/sales ratio has gone down 76.6.

Below are key valuation metrics over time for GRNA.

Stock Date P/S P/B P/E EV/EBIT
GRNA 2023-01-30 37.8 1.9 -1.1 -0.6
GRNA 2023-01-27 38.9 1.9 -1.1 -0.6
GRNA 2023-01-26 38.1 1.9 -1.1 -0.6
GRNA 2023-01-25 37.4 1.8 -1.0 -0.5
GRNA 2023-01-24 38.1 1.9 -1.1 -0.6
GRNA 2023-01-23 40.7 2.0 -1.1 -0.6

GRNA Stock Price Chart Interactive Chart >

Price chart for GRNA

GRNA Price/Volume Stats

Current price $1.09 52-week high $15.80
Prev. close $1.09 52-week low $1.00
Day low $1.07 Volume 209,100
Day high $1.16 Avg. volume 183,019
50-day MA $1.17 Dividend yield N/A
200-day MA $3.17 Market Cap 165.19M

GreenLight Biosciences Holdings, (GRNA) Company Bio


GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and a range of crops. The company was founded in 2008 and is based in Medford, Massachusetts.


GRNA Latest News Stream


Event/Time News Detail
Loading, please wait...

GRNA Latest Social Stream


Loading social stream, please wait...

View Full GRNA Social Stream

Latest GRNA News From Around the Web

Below are the latest news stories about GREENLIGHT BIOSCIENCES HOLDINGS PBC that investors may wish to consider to help them evaluate GRNA as an investment opportunity.

GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

GreenLight Biosciences lab GreenLight Biosciences lab Working toward clinical trial initiation for COVID vaccine candidate in 2023Shingles vaccine candidate selection planned for 2023 in partnership with Serum Institute of IndiaCalantha™, Colorado potato beetle solution, commercial launch planned for 2023, subject to regulatory approvalHoneybee solution EPA submission planned for 2023Strategic realignment focused on near-term value drivers. BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- GreenLight Bi

Yahoo | November 9, 2022

GreenLight Biosciences to Participate in Upcoming Investor Conferences in November

Credit Suisse annual conference GreenLight CEO Andrey Zarur will present to the Credit Suisse 31st Annual Healthcare Conference BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the potential of RNA to address some of the world’s toughest problems in human health and agriculture, today announced that Dr. Andrey Zarur, CEO, and Susan Keefe, CFO will participate in two upcoming investor conferences in November. Cred

Yahoo | November 7, 2022

GreenLight Biosciences announces realignment to focus on near-term value drivers

Colorado potato beetle on leaf Close-up of a Colorado potato beetle on a leaf BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person on our planet, today announced a realignment to focus on key near-term value drivers and extend its cash runway. Key changes include further optimizing Gree

Yahoo | October 12, 2022

GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA

Fall armyworm GreenLight's plant health research team is working to develop a solution to fall armyworm GreenLight Biosciences and Queensland University of Technology (QUT) partner to create a solution for fall armywormFall armyworm is one of the most destructive insect pests on the planet, causing more than US$2 billion in annual crop loss worldwideThe Australian government has been searching for a more environmentally-friendly solution to fall armyworm and is supporting the partnership with a

Yahoo | October 5, 2022

GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

GreenLight human health research labs GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress GreenLight raised $108.4 million in private placement led by S2G Ventures with strong participation from existing and new investors with cash expected to fund critical programs through the first half of 2023.GreenLight and Samsung Biologics completed their first commercial-scale engineering run for mRNA COVID-19 vaccine.Human health partnerships incl

Yahoo | August 15, 2022

Read More 'GRNA' Stories Here

GRNA Price Returns

1-mo -5.22%
3-mo -44.39%
6-mo -69.97%
1-year -87.64%
3-year N/A
5-year N/A
YTD -7.63%
2022 -88.10%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.754 seconds.